Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Craig Hallum

Craig Hallum began coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report issued on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.00 price objective on the stock.

Several other equities analysts have also recently weighed in on EPRX. RODMAN&RENSHAW upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company.

Eupraxia Pharmaceuticals Stock Up 2.8 %

Shares of Eupraxia Pharmaceuticals stock opened at $3.65 on Friday. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $5.15. The business has a 50 day moving average price of $3.13 and a 200-day moving average price of $2.91. The company has a market cap of $130.12 million and a PE ratio of -5.07.

Institutional Trading of Eupraxia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $31,000. Raymond James Financial Inc. purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter worth about $37,000. Finally, Bank of Montreal Can boosted its holdings in shares of Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock worth $178,000 after buying an additional 7,500 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.